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ABSTRACT
Conclusion: The detection of human papillomavirus (HPV)-DNA in oral rinse with auto-nested GP5þ/
GP6þ PCR is useful as a biomarker of oropharyngeal cancer.
Background: This study aimed to determine the usefulness of oral rinse to detect HPV-DNA as a bio-
marker of HPV-positive oropharyngeal cancer (OPC).
Patients and methods: One hundred and ten patients with various head and neck diseases, including
19 patients with OPC, were enrolled. Oral rinse and tonsillar swab were collected, and auto-nested
GP5þ/GP6þ PCR for HPV-DNA was performed. For oropharyngeal cancer, p16 immunostaining was
also conducted.
Results: The rate of HPV-DNA detection in both oral rinse and tonsillar swab was significantly higher
in OPC compared with non-OPC upper respiratory tract cancer and non-cancer diseases. HPV-DNA was
detected in oral rinse in nine out of 12 p16-positive OPC cases, while none of the p16-negative OPC
cases demonstrated detectable HPV-DNA. All p16-positive cases were also positive for HPV-DNA in
tumor tissue. Based on p16 immunostaining, the sensitivity and specificity of HPV-DNA detection in
oral rinse were 75% and 100%, respectively. Among eight of nine evaluable OPC cases positive for
HPV-DNA in oral rinse at diagnosis, HPV-DNA was undetectable in oral rinse in seven cases after
treatment.
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Human papillomavirus (HPV) is a causative agent of cer-
vical cancer [1]. On the other hand, it has become apparent
that HPV infection is a principal cause of a distinct form of
oropharyngeal cancer (OPC) [2]. According to epidemio-
logical reports, the incidence of HPV-positive OPC
increased from 16% in the 1980s to 72% in the early 2000s
in the US [3,4]. Considering the trend in the US, the inci-
dence of HPV-positive OPC is expected to increase in
Japan.
In contrast to classic OPC, HPV-related OPC generally
arises from deep crypts of palatine tonsils. Therefore, it is
difficult to detect it in the early stage with regular exami-
nations. In addition, anatomic change after surgery as well
as fibrous scar formation after chemoradiotherapy make it
difficult to visualize recurrent lesions. In consideration of
those circumstances, HPV may be an attractive target to
detect inconspicuous lesions of OPC. From this perspec-
tive, we focused on a simple and easy method, oral rinse,
to detect HPV. Here, we report the usefulness of HPV-




One hundred and ten patients with various head and neck
diseases including 19 OPCs treated in Kanazawa University
Hospital (Kanazawa, Japan) and Ishikawa Prefectural
Central Hospital (Kanazawa, Japan) were enrolled in this
study. The clinical characteristics of the patients are shown
in Table 1. This study was approved by the Ethics
Committee of Kanazawa University School of Medicine, and
Ishikawa Prefectural Central Hospital, and written consent
was obtained from all enrolled patients.
Sample collection
With respect to the oral rinse sample, 20mL of normal
saline gargled for 20 s was collected and centrifuged at
3000 rpm for 10min. The pellet was suspended in 2.0mL of
preservative solution for liquid-based cytology (Medical &
Biological Laboratories, Nagoya, Japan) and stored at 4 C
until use. With respect to the tonsillar swab sample, scratch-
ing of the palatine tonsil using a swab for uterine cervix
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cytodiagnosis was performed, and the sample was stored at
4 C until use after being suspended in a preservative
solution.
HPV-DNA detection
DNA was extracted from all samples before treatment using
a DNA extraction kit (G&G Science, Fukushima, Japan)
according to the manufacturer’s protocol. b-Globin was first
amplified by polymerase chain reaction (PCR) to confirm
the adequacy of the extracted DNA in all samples. In
b-globin-positive samples, PCR using GP5þ and
GP6þ primers, which is widely used for the detection of a
broad spectrum of mucosotropic HPV genotypes, was per-
formed [5–7]. This generates an 140-bp-long fragment from
the HPV L1 structural gene.
Samples that were negative in the first GP5þ/
GP6þPCR were re-amplified using the same set of pri-
mers, which was defined as auto-nested PCR in this study.
Thirty-six cycles and 20 cycles of amplification were per-
formed in the first and second PCR, respectively. Each
cycle consisted of 20 s at 94 C for denaturation, 30 s at
48 C for annealing, and 30 s at 72 C for extension. The
amplified DNA was subjected to electrophoresis on 2%
agarose gel, and then visualized by ultraviolet illumination
using ethidium bromide. The negative control included all
reagents except for DNA, while the p1203 PML2d HPV-16
plasmid, which was a gift from Peter Howley (Addgene
plasmid # 10869), was used as a positive control.
HPV genotyping
HPV genotyping using HPV Geno Array Test Kits
(Hybribio, Hong Kong, China) was performed according to
the manufacturer’s protocol for HPV-DNA-positive samples
[8]. This can detect 37 HPV genotypes, consisting of 15
high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, and 68), six low-risk types (6, 11, 42, 43, 44, and
CP8304), and 16 probably low-risk types (26, 34, 40, 54, 55,
57, 61, 67, 69, 70, 71, 72, 73, 82, 83, and 84), by flow-
through hybridization using HPV-DNA amplified by PCR.
Immunohistochemistry
Immunostaining for p16 was also performed in 19 OPC
cases as described previously [9]. A mouse monoclonal anti-
body against human p16 (Santa Cruz Biotechnology, Dallas,
TX) was used at a dilution of 1:200. Immunohistological p16
positivity was evaluated as described previously [10].
Statistical analysis
Differences in the age and HPV detection between p16-posi-
tive and -negative OPC were analyzed using the Mann-
Whitney U-test. The sex, smoking status, T stage, N stage,
and subsite were analyzed using two-tailed Fisher’s exact
test. All analyses were carried out using SPSS19.0 software
(SPSS Inc., Chicago, IL). In all tests, p< 0.05 was considered
significant.
Results
HPV-DNA detection in head and neck diseases
b-Globin was detected in all oral rinse and tonsillar swab
samples. With respect to HPV-DNA detection, adding the
second PCR clearly increased the detection threshold, as
shown in Figure 1. In accordance, most HPV-DNA-positive
samples were identified using the second PCR in both oral
rinse and tonsillar swab in the present study, as shown in
case 2 of Figure 2.
One hundred and ten cases were divided into three
groups: OPC, upper respiratory tract cancer other than OPC
(URTC), and non-cancer. In oral rinse, HPV-DNA was
detected in nine of 19 cases (47.4%) with OPC, eight of 47
cases (17.0%) with URTC, and seven of 44 cases (15.9%)
with non-cancer (Table 2). In tonsillar swab, HPV-DNA was
Figure 1. Detection of HPV-DNA in the first and second PCR using gradient concentrations of the positive control.
Table 1. Patient characteristics.
Number
of patients Male Female
Mean
age (years)
Upper respiratory tract cancer 66 56 10 65.3
Oropharyx 19 15 4 65.3
Larynx 15 15 0
Hypopharynx 13 13 0
9>>=
>>;
Oral cavity 9 7 2 65.3
Nasopharynx 7 5 2
Others 3 1 2
Non-cancer 44 18 26 54.5
Sinonasal disease 15 3 12
Thyroid tumor 8 2 6
Benign laryngeal disease 7 6 1
Ear disease 7 4 3
Salivary gland tumor 3 2 1
Others 4 1 3
Total 110 74 36 60.4
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detected in 10 of 19 cases (52.6%) with OPC, four of 47
cases (8.5%) with URTC, and four of 44 cases (9.1%) with
non-cancer (Table 2). The concordance of HPV-DNA detec-
tion between oral rinse and tonsillar swab was 94.7% in
OPC, 85.1% in URTC, and 79.5% in non-cancer.
HPV-DNA detection and p16 immunohistochemistry in
oropharyngeal cancer
Because almost half of the cases with OPC were positive for
HPV-DNA in both oral rinse and tonsillar swab, we next
investigated the association with p16 immunostaining in
OPC. The clinical characteristics of OPC patients are shown
in Table 3. Twelve of the 19 OPC cases were positive for
p16, while the remaining seven were negative. There were
no significant differences with respect to the sex, smoking
status, T stage, N stage, or tumor sub-site between p16-posi-
tive and -negative cases.
In addition, we also performed PCR using GP5þ/
GP6þ primers to detect HPV-DNA in samples obtained
from formalin-fixed paraffin-embedded tissue of OPC, and
demonstrated that all p16-positive cases were also positive
for HPV-DNA. Therefore, there was no p16-positive case
who was negative for HPV in the present study.
In oral rinse, HPV-DNA was detected in nine of 12 p16-
positive cases, while none of the seven p16-negative cases
demonstrated HPV-DNA, showing a significant difference
(p¼ 0.003) (Table 4, Figure 2). Similarly, in tonsillar swab,
HPV-DNA was detected in 10 of 12 cases, while none of the
seven p16-negative cases demonstrated HPV-DNA, showing
a significant difference (p¼ 0.001) (Table 4, Figure 2). Based
on p16 immunostaining, the sensitivity, specificity, positive
predictive value, and negative predictive value of HPV-DNA
detection in oral rinse and tonsillar swab were 75, 100, 100,
and 70%, and 83, 100, 100, and 78%, respectively.
HPV-DNA detection in oral rinse after treatment in
oropharyngeal cancer
Eight of nine OPC patients positive for HPV-DNA in oral
rinse at diagnosis were further investigated after treatment
(Table 5). In these eight, oral rinse samples were collected
5–15 months (mean¼ 9.6 months) after the completion
of treatment. As shown in Table 5, HPV-DNA was
undetectable in oral rinse in seven of eight cases after treat-
ment, while the remaining case was positive for HPV-DNA.
Four were treated with chemoradiotherapy, and four were
Figure 2. HPV-DNA detection in oropharyngeal cancer cases. Cases 1 and 2 are p16-positive, while case 3 is p16-negative. PC: positive control; OR: oral rinse; NC:
negative control; NS: non-specific band.
Table 2. Positive rate of HPV-DNA detection in oral rinse and tonsillar swab.
Oral rinse Tonsillar swab
Oropharyngeal cancer 9/19 (47.4%) 10/19 (52.6%)
Non-oropharyngeal upper respiratory
tract cancer
8/47 (17.0%) 4/47 (8.5%)
Non-cancer 7/44 (15.9%) 4/44 (9.1%)
Table 3. Characteristics of oropharyngeal cancer patients.
p16 immunostaining
Positive Negative p-value
Number of patients 12 7




















Base of tongue 3 4
Table 4. Comparison between HPV-DNA detec-
tion and p16 immunostaining.
p16
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treated with surgery. All patients achieved a complete
response after treatment, and were without any evidence of
disease at sample collection.
HPV genotyping
HPV genotyping was further performed in 42 samples with
HPV-DNA detection. A certain HPV genotype was detected
in only 14 (35.0%) samples, while no types of HPV were
detected in the remaining samples. In p16-positive OPC,
HPV type 16 (HPV16) was detected in four of nine oral
rinse samples, and four of 10 tonsillar samples, while HPV
type 58 was detected in one tonsillar swab sample. On the
other hand, HPV genotyping from tissues of OPC patients
identified HPV16 in 11 of 12 p16-positive OPC cases and
HPV58 in the remaining case. In non-oropharyngeal URTC
samples, HPV16 was detected in one of eight cases which
were HPV-positive in oral rinse samples, and one of four
tonsillar swab samples. In non-cancer samples, HPV16 was
detected in three of 15 cases which were HPV-positive in
oral rinse samples, and three of eight tonsillar swab samples.
Only a single sub-type of HPV could be detected in all
evaluable samples.
Discussion
The prevalence of oral HPV infection among healthy persons
was reported to be 5.7–8.3% in the US [2]. On the other
hand, the HPV-positive rate in oral rinse in non-cancer
patients was 15.9% in the present study, being higher than in
previous reports. Adding a second PCR may increase the
detection threshold, while a difference in the patient back-
ground may affect the positive rate. Accordingly, the avail-
ability of auto-nested GP5þ/GP6þPCR to detect HPV-DNA
was described by Remmerbache et al. [7]. Furthermore, the
increased sensitivity of auto-nested GP5þ/GP6þPCR com-
pared with conventional single-round GP5þ/GP6þ PCR was
demonstrated [11]. Thus, auto-nested PCR may be a useful
method to investigate samples with low viral loads [11].
This was also supported by the fact that only one third of the
samples with HPV-DNA detection identified certain HPV
subtypes in the present study, which suggests the higher
detection sensitivity of auto-nested PCR than the regular gen-
otyping kit.
There have been several reports with respect to HPV-
DNA detection in oral rinse, showing positive rates from
39–54% in HPV-related OPC [12–14]. In comparison with
these reports, the present study demonstrated a higher posi-
tive rate of 75% in p16-positive OPC. This is in accordance
with the favorable result of auto-nested PCR as described
above.
HPV-DNA was not detected in oral rinse in three p16-
positive OPC cases. Among them, two involved OPC arising
at the base of the tongue, and showing a submucosal
appearance. Thus, the HPV-DNA detection rate in p16-posi-
tive OPC was 89% (eight of nine) at sub-sites of the tonsil,
and 33% (one of three) at the base of the tongue. Therefore,
it is considered that HPV-DNA in oral rinse could be more
detectable in OPC in the tonsil than at the base of the
tongue. Wang et al. [14] similarly reported a higher detec-
tion rate in HPV-related OPC of the tonsil (67%) than at
the base of the tongue (24%).
In the present study, the concordance rate of HPV-DNA
detection between oral rinse and tonsillar swab was 94.7%
in OPC, 85.1% in URTC, and 79.5% in non-cancer. In add-
ition, based on p16 immunostaining, the sensitivity and spe-
cificity of HPV-DNA detection were 75% (nine of 12) and
100% (seven of seven) in oral rinse, and 83.3% (10 of 12)
and 100% (seven of seven) in tonsillar swab, respectively. A
high concordance rate suggests the usefulness of unobstruc-
tive sample collection, namely oral rinse, being in accord-
ance with a study comparing oral rinse and cytology brush
sampling [15].
Interestingly, HPV-DNA in oral rinse after treatment
became negative in seven of eight evaluable cases. Although
we did not observe any recurrent cases among these eight
patients, HPV-DNA in oral rinse after treatment could be a
biomarker of the disease status. Rettig et al. [12] demon-
strated that persistent HPV16 DNA in oral rinse after treat-
ment was associated with poorer disease-free survival and
overall survival. Further research with respect to the preva-
lence of HPV-DNA in oral rinse after treatment detected
with our strategy is warranted.
One of the limitations of the present study is the small
number of cases of OPC. However, we could at least dem-
onstrate the superiority of our method to detect HPV-
DNA in oral rinse. Another limitation is the relatively
short period of post-treatment observation. Actually, it is
unclear whether persistent HPV-DNA in oral rinse after
treatment detected with our procedure is associated with
persistent disease, or whether HPV-DNA will be
re-detected in cases of disease recurrence at the primary
site. Another limitation is the low rate of HPV genotyping
in oral rinse samples. The HPV genotyping procedure
included one round of PCR consisting of 40 cycles accord-
ing to the manufacturer’s protocol, while the second PCR
was added after the first PCR to identify HPV-DNA in
oral rinse samples in the present study. Therefore, we con-
sider that the procedural difference between genotyping
and auto-nested PCR was a major reason for the low rate
of HPV genotyping in oral rinse samples. Further study is
planned to answer these limitations.
Table 5. Comparison of HPV-DNA detection in oral rinse before and after
treatment in p16-positive oropharyngeal cancer.
HPV-DNA detection
in oral rinse
Case Subsite TNM Before After State
1 Tonsil T3N2cM0 þ  CR
2 Tonsil T1N2bM0 þ  CR
3 Tonsil T3N0M0 þ  CR
4 Tonsil T1N2bM0 þ  CR
5 Tonsil T2N2cM0 þ þ CR
6 Tonsil T2N2bM0 þ  CR
7 Tonsil T2N0M0 þ  CR
8 Tonsil T2N2bM0 þ  CR
CR: Complete response.
776 H. YOSHIDA ET AL.
Conclusion
In conclusion, HPV-DNA detection in oral rinse is useful as
a biomarker of HPV-related OPC. Auto-nested GP5þ/
GP6þPCR was a helpful method for this purpose.
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